Novo Nordisk A/S Stock Price and Value Analysis

Should you buy Novo Nordisk A/S stock? (NYSE:NVO). Let's see how it does in our automated value investing analysis system.

  • This company has amazingly consistent growth!
  • This company is less known than others.
  • This stock looks overpriced.
  • This company has a low dividend yield.
  • This company is not making money.

Inside the NVO Numbers

NVO Price
(Novo Nordisk A/S stock price per share)
[?] PE Ratio versus Sector 125% higher than other Healthcare stocks
[?] PE Ratio versus Industry 20% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 0%
[?] Dividend Yield 1%
Shares Shorted 3,220,468

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 3,220,468 shares shorted. With 1,618,597,668 shares available for purchase and an average trading volume over the past 10 trading days of 1,224,850, it would take at least 2.629 days for all of the short holders to cover their shorts.

Is Novo Nordisk A/S Stock on Sale?

Based on our analysis, we believe that you should not buy Novo Nordisk A/S right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy NVO Stock?

Does Novo Nordisk A/S have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.